ERBB2 and neoplasm: Another case concerning HER2+ DTCs (ID 3306) was diagnosed with TNBC in 09/2022 and the resected tumor tissue turned out to be HER2 low (Score 1+) and PD-L1 positive (TPS 1, CPS 4) with an Ki67 index of 80%, while pCR was reached and pembrolizumab was administered.